News
news New biometric database can identify people through scars, tattoos and even their voice
news Cattle Are Being Mutilated And Killed In Eastern Oregon
news Insider Interview on Skinwalker Ranch History
news Squirrels Can Speak Bird
news US Navy pilot says mystery ‘dark mass’ emerged from ocean and swallowed torpedo
news Cognitive scientist says we see things as we need to, rather than as they are.
news A Movie You Control With Your Mind
news Radioactive Cloud That Blanketed Europe Traced to Russian Nuclear Facility
news Organization Says It’s Obtained ‘Exotic’ Metals Unknown to Science
news The frightening supernatural story of the Black Bird of Chernobyl
news Recent UFO Encounters With Navy Pilots Occurred Constantly Across Multiple Squadrons


Username:
Password: or Register
 
Thread Rating:
  • 13 Vote(s) - 3.46 Average
  • 1
  • 2
  • 3
  • 4
  • 5

Morocco Gives Green Light For Its Hospitals to Use Antimalarial Drugs to Fight Covid
Convicted Criminal
Registered User
User ID: 433612
05-29-2020 08:14 AM

Posts: 6,428




Post: #2101
RE: Morocco Gives Green Light For Its Hospitals to Use Antimalarial Drugs to Fight Covid
Advertisement
Convicted Criminal  Wrote: (05-29-2020 08:14 AM)
Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis

https://academic.oup.com/aje/advance-art...93/5847586

More than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality. An outpatient treatment that prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September. Early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease. Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000 Americans now dying each week. These medications need to be widely available and promoted immediately for physicians to prescribe.

BumpBumpBump
Quote this message in a reply
Convicted Criminal
Registered User
User ID: 433612
05-29-2020 08:38 AM

Posts: 6,428




Post: #2102
RE: Morocco Gives Green Light For Its Hospitals to Use Antimalarial Drugs to Fight Covid
Covid-19 study on hydroxychloroquine use questioned by 120 researchers and medical professionals

https://www.theguardian.com/world/2020/m...fessionals

More than 120 researchers and medical professionals from around the world have written an open letter to the editor of the Lancet raising serious concerns about a large and widely publicised global study that prompted the World Health Organisation to halt several Covid-19 clinical trials.

On Thursday Guardian Australia revealed that the Australian data in the study, published last week, did not reconcile with health department records or databases.

The study found Covid-19 patients who received the malaria drug hydroxychloroquine were dying at higher rates and experiencing more heart-related complications than other virus patients. The large observational study analysed data from nearly 15,000 patients with Covid-19 who received the drug alone or in combination with antibiotics, comparing this data with 81,000 controls who did not receive the drug.

Questions about the paper’s statistical modelling were also raised by Columbia University in the US, prompting Surgisphere, the company that manages the database of patients used to inform the study, to issue a public statement defending the integrity of the study.

But now further questions have been raised about the Surgisphere database and the study methodology. The signatories to the open letter, directed to the Lancet and the study authors, include prominent sceptics of the value of using hydroxychloroquine to treat Covid-19. The letter lists 10 major concerns about the statistical analysis and data integrity of the study.

“The authors have not adhered to standard practices in the machine learning and statistics community,” the letter states. “They have not released their code or data.”
Quote this message in a reply
Convicted Criminal
Registered User
User ID: 433612
05-29-2020 08:34 PM

Posts: 6,428




Post: #2103
RE: Morocco Gives Green Light For Its Hospitals to Use Antimalarial Drugs to Fight Covid
Quote this message in a reply
Convicted Criminal
Registered User
User ID: 433612
05-29-2020 08:51 PM

Posts: 6,428




Post: #2104
RE: Morocco Gives Green Light For Its Hospitals to Use Antimalarial Drugs to Fight Covid
Quote this message in a reply
Convicted Criminal
Registered User
User ID: 433612
Yesterday 08:07 PM

Posts: 6,428




Post: #2105
RE: Morocco Gives Green Light For Its Hospitals to Use Antimalarial Drugs to Fight Covid
I was talking to a woman from Vietnam on tinder and she was saying that her country has zero deaths recently and the pandemic is completely over there, where she lives.

***

It's true that Vietnam did use lots of chloroquine on COVID-19.

LINK: https://clinicaltrials.gov/ct2/show/NCT04328493

COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent COVID-19 or therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate potential therapeutics for the treatment of hospitalized COVID-19.

We hypothesis that chloroquine slows viral replication in patients with COVID-19, attenuating the infection, and resulting in more rapid declines in viral load in throat swabs. This viral attenuation should be associated with improved patient outcomes. Given the enormous experience of its use in malaria chemoprophylaxis, excellent safety and tolerability profile, and its very low cost, if proved effective then chloroquine would be a readily deployable and affordable treatment for patients with COVID-19.

The study is funded and leaded by The Ministry of Health, Vietnam.
(This post was last modified: Yesterday 09:05 PM by Convicted Criminal.) Quote this message in a reply








Contact UsConspiracy Forum. No reg. required! Return to TopReturn to ContentRSS Syndication